Hong Kong stock Jingtai Holdings plunged nearly 15%, and the company's 1.464 million restricted shares are expected to circulate freely from today.Good wife set up an intelligent technology company in Quanzhou, and the enterprise search APP shows that Quanzhou Sunguest Intelligent Technology Co., Ltd. was established recently, with the legal representative of Cao Caifeng and the registered capital of 500,000 yuan. Its business scope includes: engineering and technical research and experimental development; Network and information security software development; Software development; Digital technology services, etc. Enterprise equity penetration shows that the company is wholly owned by Haotai.Real estate stocks fluctuated lower, with Gorgeous Family, Qixia Construction, Everbright Jiabao and Tiandiyuan falling more than 5%, while urban construction development and Chongqing development followed suit.
The central bank's open market today launched a 7-day reverse repurchase operation of 205.1 billion yuan, and the operating interest rate was flat at 1.50%. Today, 190.9 billion yuan of 7-day reverse repurchase expired, and the net investment on that day was 14.2 billion yuan.Maotai Group had an exchange discussion with Huawei. Kweichow Moutai official news on December 13th. On December 12th, Zhang Pingan, managing director of Huawei Technologies Co., Ltd. and CEO of Huawei Cloud, visited Maotai and held an exchange discussion with Zhang Deqin, Party Secretary and Chairman of Maotai Group.The T-shaped overpass with the longest and heaviest single span in China successfully turned and crossed Panxi Railway. According to The Paper, on the afternoon of December 11th, after 82 minutes of continuous construction, the T-shaped overpass with the longest and heaviest single span in China turned 52 degrees clockwise from Panxi Railway Vehicle Turning Station to Yangweishao Station under the jurisdiction of Kunming Bureau of China Railway, realizing a "gorgeous turn" and successfully completed the turn across Panxi Railway.
Look at the picture: The increased confidence of Japan's large-scale manufacturing industry indicates that the economic development is in line with the Bank of Japan's forecast. Before the Bank of Japan's policy meeting next week, the confidence of Japan's large-scale manufacturing industry has increased. According to the quarterly short-term report released by the Bank of Japan on Friday, the short-term survey index of Japan's large manufacturing industry rose slightly to 14 in December, with an estimated 13. The short-term survey index of large non-manufacturing industry decreased slightly from 34 to 33. Small businesses' confidence in manufacturing and service industries has also improved, although the outlook has slightly weakened or remained unchanged. The short-term report has attracted the attention of the Bank of Japan and is the last batch of major domestic data that will be carefully studied before the interest rate decision on December 19. This result shows that Japan's economic development is in line with the forecast of the Bank of Japan and is a condition for further interest rate hike. Compared with December, economists are more inclined to expect the Bank of Japan to take action in January next year, but still believe that the risk of raising interest rates next week is high.Guojin Securities: The warm wind of medical policy comes first, then the progress of innovation going out to sea, and then the opportunity of performance reversal. Guojin Securities Research Report said that the core investment opportunities in the pharmaceutical sector in 25 years will revolve around three logics: 1) innovation going out to sea; 2) demand recovery; 3) Policy expectation reversal. At present, the policy warm wind comes first (the medical track policy continues to warm up, and the overall industry expectation is expected to be optimistic); Then, R&D and innovation will go to sea (innovative drug track will continue to make progress, and it will still be the hottest track in the pharmaceutical sector in 2025, especially it is recommended to pay attention to the clinical data reading and commercialization progress of the first-line target, as well as the fluctuation opportunity of the expected difference of the second-line innovative drugs), and then the performance growth rate is expected to bottom out in the first half of 2025 (but it will take time for this improvement in performance growth rate to come. Considering the current industry communication and historical base, it is expected that 4Q24 and 1Q25 should still be cautiously optimistic.)Party Committee of CITIC Group: Firmly support the CPC Central Committee's decision to punish Xu Zuo. According to the news of CITIC Group official micro on December 13th, recently, the Party Committee of CITIC Group held a meeting to convey the decision of the State Supervision Commission of the Central Commission for Discipline Inspection to punish Xu Zuo. Xi Guohua, secretary and chairman of the Party Committee, presided over the meeting and made a speech, and members of the Party Committee made statements. Comrades attending the meeting unanimously expressed their firm support for the decision of the CPC Central Committee and the decision of the State Supervision Commission of the Central Commission for Discipline Inspection.
Strategy guide
Strategy guide
Strategy guide 12-13
Strategy guide